<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03898973</url>
  </required_header>
  <id_info>
    <org_study_id>50328</org_study_id>
    <nct_id>NCT03898973</nct_id>
  </id_info>
  <brief_title>Response to Inactivated Influenza Vaccine in Lymph Tissue and Blood</brief_title>
  <acronym>FLU-LN</acronym>
  <official_title>Response to Inactivated Influenza Vaccine in Lymph Tissue and Blood</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is one project of a larger ongoing study related to the immune system's response to the&#xD;
      flu virus. This study is designed to determine how immune memory develops at the actual site&#xD;
      of exposure, and how immunization may alter this process.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase IV study of licensed influenza vaccines with up to 50 volunteers, 20-75 years&#xD;
      of age.&#xD;
&#xD;
      Each volunteer will participate for approximately 1 week including enrollment, vaccination,&#xD;
      and completion of sample collection.&#xD;
&#xD;
      The study has a total of 3 visits.&#xD;
&#xD;
      Study Procedures:&#xD;
&#xD;
      Screening Visit: Procedures during this visit are: Informed consent process, assess&#xD;
      eligibility collect relevant clinical data and obtain 10 mL of blood to ensure the FNA will&#xD;
      be safe (acceptable CBC and PT/PTT).&#xD;
&#xD;
      Visit 1: Vaccination Visit:&#xD;
&#xD;
      Eligible subjects will return and have a 20 mL blood sample. Participants will receive the&#xD;
      inactivated flu vaccine into the right anterior quadriceps. Volunteers will be monitored for&#xD;
      at least 15 minutes after study vaccination.&#xD;
&#xD;
      Visit 2: FNA Procedure: Seven days after vaccination the participant will return for another&#xD;
      collection of 20 ml of blood and a fine needle aspiration of a right inguinal lymph node&#xD;
      under ultrasound guidance by a trained pathologist.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 11, 2019</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HAI titer</measure>
    <time_frame>Day 7 after vaccination</time_frame>
    <description>This measures response to influenza vaccine</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Study Phase</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will be given the current year's a quadrivalent inactivated influenza vaccine (IIV)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent inactivated influenza vaccine (IIV)</intervention_name>
    <description>Intramuscular Injection. Participants will receive the inactivated flu vaccine into anterior quadriceps.</description>
    <arm_group_label>Study Phase</arm_group_label>
    <other_name>Fluzone Quadrivalent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 20-75-year-old male and female patients&#xD;
&#xD;
          2. Body mass index (BMI) 20-35 kg/m2&#xD;
&#xD;
          3. Acceptable laboratory values: Absolute neutrophil count (ANC) &gt; 750 cells/mm3;&#xD;
             Hemoglobin &gt;10 g/dL; Platelet count &gt;75,000/mm3; Partial thromboplastin time (PTT)&#xD;
             &gt;1.2x ULN; Prothrombin time (PT) &gt;1.2x ULN&#xD;
&#xD;
          4. Willing and able to complete the informed consent process&#xD;
&#xD;
          5. Availability for follow-up for the planned duration of the study&#xD;
&#xD;
          6. Acceptable medical history by review of inclusion/exclusion criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior off-study vaccination with seasonal influenza vaccine within three months of&#xD;
             study vaccination&#xD;
&#xD;
          2. Life-threatening reactions to previous influenza vaccinations&#xD;
&#xD;
          3. Allergy to egg or egg products or to vaccine components&#xD;
&#xD;
          4. Active systemic or serious concurrent illness, including febrile illness on the day of&#xD;
             vaccination&#xD;
&#xD;
          5. History of immunodeficiency (including HIV infection)&#xD;
&#xD;
          6. Known or suspected impairment of immunologic function; may include significant liver&#xD;
             disease, diabetes mellitus treated with insulin or moderate to severe renal disease&#xD;
&#xD;
          7. Chronic Hepatitis B or C.&#xD;
&#xD;
          8. Recent or current use of immunosuppressive medication, including systemic&#xD;
             glucocorticoids (corticosteroid nasal sprays and topical steroids are permissible).&#xD;
             Use of oral steroids (&lt;20mg prednisone-equivalent/day) may be acceptable after review&#xD;
             by the investigator.&#xD;
&#xD;
          9. Malignancy, other than squamous cell or basal cell skin cancer (includes solid tumors&#xD;
             such as breast cancer or prostate cancer with recurrence in the past year, and any&#xD;
             hematologic cancer such as leukemia).&#xD;
&#xD;
         10. Autoimmune disease (including rheumatoid arthritis treated with immunosuppressive&#xD;
             medication such as Plaquenil, methotrexate, prednisone, Enbrel) which, in the opinion&#xD;
             of the investigator might jeopardize volunteer safety or compliance with the protocol.&#xD;
&#xD;
         11. History of blood dyscrasias, renal disease, or hemoglobinopathies requiring regular&#xD;
             medical follow up or hospitalization during the preceding year&#xD;
&#xD;
         12. Use of any anti-coagulation medication such as Coumadin or Lovenox, or anti-platelet&#xD;
             agents such as aspirin (except up to 325 mg per day), Plavix, or Aggrenox will be&#xD;
             reviewed by investigators to determine if study participation would affect the&#xD;
             volunteer's safety or compliance with the protocol.&#xD;
&#xD;
         13. Receipt of blood or blood products within the past 6 months or planned used during the&#xD;
             study.&#xD;
&#xD;
         14. A medical or psychiatric condition or occupational responsibilities that preclude&#xD;
             participant compliance with the protocol&#xD;
&#xD;
         15. Receipt of an inactivated vaccine 14 days prior to study enrollment, or planned&#xD;
             vaccinations prior to completion of last annual study visit (~ 28 days after study&#xD;
             vaccination)&#xD;
&#xD;
         16. Receipt of a live, attenuated vaccine within 60 days prior to enrollment of planned&#xD;
             vaccination prior to completion of last study visit (~ 28 days after study enrollment)&#xD;
&#xD;
         17. Need for allergy immunization (that cannot be postponed) until after the last study&#xD;
             visit.&#xD;
&#xD;
         18. History of Guillain-Barre# syndrome&#xD;
&#xD;
         19. Use of investigational agents within 30 days prior to enrollment or planned use during&#xD;
             the study.&#xD;
&#xD;
         20. Donation of the equivalent of a unit of blood within 6 weeks prior to enrollment or&#xD;
             donation of platelets within 2 weeks of enrollment or planned donation prior to&#xD;
             completion of the last visit.&#xD;
&#xD;
         21. Pregnancy&#xD;
&#xD;
         22. Any condition which, in the opinion of the investigator, might interfere with&#xD;
             volunteer safety,&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford University Medical Center, Lane building L134</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 30, 2019</study_first_submitted>
  <study_first_submitted_qc>March 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2019</study_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Philip Grant</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine (Infectious Diseases)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

